US2008227114A1PendingUtilityA1

Compositions and methods for modulating c-rel-dependent cytokine production

Assignee: SYNTA PHARMACEUTICALS CORPPriority: Nov 10, 2003Filed: Jan 10, 2008Published: Sep 18, 2008
Est. expiryNov 10, 2023(expired)· nominal 20-yr term from priority
A61P 37/00A61P 37/06A61P 3/10A61P 7/06A61P 37/02A61P 7/00A61P 25/16A61P 27/16A61P 29/00A61P 25/32A61P 25/28A61P 27/02A61P 25/14A61P 25/00A61P 25/06A61P 11/00A61P 17/02A61P 13/12A61P 1/02G01N 33/6872G01N 2333/4703A61P 1/16A61P 19/10A61P 15/02G01N 33/5035A61P 11/06A61P 17/00A61P 17/06A61P 19/00G01N 2333/54A61P 17/14G01N 2500/10A61P 21/04A61P 19/02A61P 1/04
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed to compositions and methods for modulating c-Rel-dependent cytokine production without materially altering the level of expression of NFκB and/or the amount of IκB. The present invention is also directed to screening for modulators of c-Rel activity as determined by assaying for altered subcellular localization of c-Rel but where the level of expression of NFκB and/or the amount of IκB is materially unaltered.

Claims

exact text as granted — not AI-modified
1 . A method of identifying a molecule that alters the subcellular location of c-Rel in a cell comprising:
 (a) contacting the cell with one or more candidate molecules; and   (b) detecting localization of c-Rel molecules in the cell,   
       wherein an increase or decrease in the amount of c-Rel localized to the nucleus without materially altering the level of expression of NFκB and/or amount of IκB relative to said amount in a cell not so contacted with the one or more candidate molecules indicates that the candidate molecules alter the subcellular localization of c-Rel. 
     
     
         2 . A method of identifying a molecule that alters the subcellular location of c-Rel in a cell comprising:
 (a) recombinantly expressing within the cell one or more candidate molecules; and   (b) detecting localization of c-Rel molecules in the cell,   
       wherein an increase or decrease in the amount of c-Rel localized to the nucleus without materially altering the level of expression of NFκB and/or amount of IκB relative to said amount in a cell in which the one or more candidate molecules were not so expressed indicates that the candidate molecules alter the subcellular localization of c-Rel. 
     
     
         3 . The method according to  claim 1  wherein step (b) comprises contacting the cell with an antibody to c-Rel or a binding region of said antibody, and a fluorescently labeled binding partner of said antibody under conditions conducive to immunospecific binding. 
     
     
         4 . The method according to  claim 1  wherein step (b) comprises contacting the cell with a fluorescently labeled antibody to c-Rel or a binding region of said antibody under conditions conducive to immunospecific binding. 
     
     
         5 . The method according to  claim 1  wherein step (b) comprises sequencing by mass spectroscopy nuclear proteins isolated from the cell. 
     
     
         6 . The method according to  claim 1  wherein the cell is a cultured cell. 
     
     
         7 . A method of identifying a molecule that alters the subcellular location of c-Rel in a cell comprising:
 (a) microinjecting into the cell one or more candidate molecules; and   (b) detecting localization of c-Rel molecules in the cell,   
       wherein an increase or decrease in the amount of c-Rel localized to the nucleus without materially altering the level of expression of NFκB and/or amount of IκB relative to said amount in a cell not so microinjected with the one or more candidate molecules indicates that the candidate molecules alter the subcellular localization of c-Rel. 
     
     
         8 . A method for screening for a molecule that modulates directly or indirectly c-Rel activity comprising:
 (a) contacting a cell expressing c-Rel with one or more candidate molecules; and   (b) detecting the levels of c-Rel localized to the nucleus in said cell without materially altering the level of expression of NFκB and/or amount of IκB relative to said levels in a cell not contacted with said candidate molecules,   
       wherein a higher or lower level of c-Rel localization to the nucleus in the presence of said candidate molecules indicates that the molecules modulate the activity of c-Rel. 
     
     
         9 . A method for screening for a molecule that modulates directly or indirectly c-Rel activity comprising:
 (a) recombinantly expressing one or more candidate molecules within a cell expressing c-Rel; and   (b) detecting the levels of c-Rel localized to the nucleus in said cell without materially altering the level of expression of NFκB and/or amount of IκB relative to said levels in a cell in which candidate molecules were not so expressed,   
       wherein a higher or lower level of c-Rel localization to the nucleus in the presence of said candidate molecules indicates that the molecules modulate the activity of c-Rel. 
     
     
         10 . The method according to  claim 8  wherein the candidate molecule decreases the amount of c-Rel localization to the nucleus, thereby being a candidate inhibitor of c-Rel activity. 
     
     
         11 . The method according to  claim 8  wherein the candidate molecule increases the amount of c-Rel localization to the nucleus, thereby being a candidate agonist of c-Rel activity. 
     
     
         12 . The method according to  claim 8  wherein the candidate molecules are derived from a constrained random peptide library. 
     
     
         13 . The method according to  claim 8  wherein c-Rel localization to the nucleus is detected by a method comprising contacting the cell with a molecule that binds to c-Rel and a molecule that binds to a nuclear-specific protein other than c-Rel under conditions conducive to binding, and detecting any binding of the molecules to the same subcellular location that occurs. 
     
     
         14 . The method according to  claim 8  wherein step (b) comprises contacting the cell with a fluorescently labeled antibody to c-Rel or a binding region of the antibody under conditions conducive to immunospecific binding.

Join the waitlist — get patent alerts

Track US2008227114A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.